Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Oncology, Screening and monitoring

A Ray of Hope Against Aggressive Cancers

One possible culprit for immortality in human cancer cells is the presence of human telomerase reverse transcriptase (hTERT) activity. The correlation between hTERT’s enzymatic activity and TERT expression levels in cancer has yet to be fully understood, but – building on previous work that established hTERT phosphorylation at threonine 249 (p-hTERT) in specific liver and pancreatic cancers – a Japanese research team has now identified that phosphorylated hTERT is common in many cancers with more aggressive characteristics.

The team developed a mouse monoclonal antibody capable of recognizing phosphorylated hTERT at threonine 249, reportedly the first effective tool for visualizing hTERT-RdRP in cancer through formalin-fixed, paraffin-embedded tissues. They then analyzed 1,523 cancer specimens with a variety of sites of origin to better understand the clinicopathological characteristics of hTERT-RdRP-active cancer.

The results showed that p-hTERT is associated with higher overall risk in aggressive lung, pancreatic, and liver cancers – regardless of TNM staging. Expression of p-hTERT is also strongly associated with “markers of squamous cell differentiation and aggressive features,” indicating that this process is common in aggressive cancers. The team discovered that p-hTERT is associated with a number of oncological features such as “adenosquamous carcinoma (lung and pancreas), invasive type of cancer (lung), high serum alpha-fetoprotein level (liver), and triple-negative status (breast)” (1). 

Though p-hTERT may have prognostic value in lung, pancreatic, and liver cancers, this was not evidenced in colon and stomach cancers. The team also discovered that, although p-hTERT expression increased alongside mitosis score in all of the aforementioned cancers, expression in colon and stomach cancers decreased as pathological grade increased. One potential reason for this difference is that other mechanisms, possibly in the tumor microenvironment, may regulate p-hTERT expression in these cancers.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. Y Matsuda et al., J Pathol, 257, 172 (2022). PMID: 35094384.
About the Author
George Francis Lee

Associate Editor, The Pathologist

Like most people, I didn’t know exactly what I wanted to do after university. But one thing was certain – writing would play a central role. Not one to walk the path most traveled, I decided to spend my next few years freelancing to hone my skills as a writer and further cement my love for language. Reaching people through writing is important to me and I look forward to connecting with thousands of people through Texere’s passionate audience.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine